KDR and inflammatory breast carcinoma: An interesting rather new tissue biomarker is phospho-VEGFR2: in patients with inflammatory breast cancer, anti-angiogenic therapies resulted in a reduction of phospho-VEGFR2, associated with an increase in tumor cell apoptosis and no change in tumor cell proliferation [33].